Erratum: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination (PLoS Pathogens (2016) 12:3 (e1005456) DOI: 10.1371/journal.ppat.1005456);Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination

PLoS Pathogens

Volumn 12, Issue 3, 2016, Pages

  Mahan, Alison E ^a   Jennewein, Madeleine F ^a   Suscovich, Todd ^a   Dionne, Kendall ^a   Tedesco, Jacquelynne ^a   Chung, Amy W ^a   Streeck, Hendrik ^b   Pau, Maria ^c   Schuitemaker, Hanneke ^c,d   Francis, Don ^e   Fast, Patricia ^f   Laufer, Dagna ^f   Walker, Bruce D ^a   Baden, Lindsey ^g   Barouch, Dan H ^a,h   Alter, Galit ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Walter Reed Medical Center   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Global Solutions for Infectious Diseases   (United States)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; GLYCOSYLATED IGG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN SPECIFICITY; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PHAGOCYTOSIS; VACCINATION; COHORT ANALYSIS; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COHORT STUDIES; FEMALE; GLYCOSYLATION; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MALE; PHAGOCYTOSIS; VACCINATION;

EID: 84962467040     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005694     Document Type: Erratum

References (43)

1. Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. Nature Publishing Group; 2007;449: 101–4. doi: 10.1038/nature0610617805298
2. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, Menezes J, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol. 2001;21: 227–33. Available: http://www.ncbi.nlm.nih.gov/pubmed/1140323011403230
3. Co MDT, Terajima M, Thomas SJ, Jarman RG, Rungrojcharoenkit K, Fernandez S, et al. Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children. Viral Immunol. 2014;27: 375–82. doi: 10.1089/vim.2014.006125141276
4. Kajihara M, Marzi A, Nakayama E, Noda T, Kuroda M, Manzoor R, et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol. 2012;86: 13467–74. doi: 10.1128/JVI.01896-1223035224
5. Pizza M, Rappuoli R, Neisseria meningitidis: pathogenesis and immunity. Curr Opin Microbiol. 2014;23C: 68–72. doi: 10.1016/j.mib.2014.11.006
6. Jefferis R, Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7: 1401–13. doi: 10.1517/14712598.7.9.140117727329
7. Hamilton RG, Human IgG subclass measurements in the clinical laboratory. Clin Chem. 1987;33: 1707–25. Available: http://www.ncbi.nlm.nih.gov/pubmed/33114623311462
8. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014;6: 228ra38. doi: 10.1126/scitranslmed.300773624648341
9. Morell A, Terry WD, Waldmann TA, Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49: 673–80. doi: 10.1172/JCI1062795443170
10. Lux A, Nimmerjahn F, Impact of differential glycosylation on IgG activity. Adv Exp Med Biol. 2011;780: 113–24. doi: 10.1007/978-1-4419-5632-3_1021842369
11. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA, The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. Annual Reviews; 2007;25: 21–50. doi: 10.1146/annurev.immunol.25.022106.14170217029568
12. Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc??RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277: 26733–26740. doi: 10.1074/jbc.M20206920011986321
13. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M, Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng. 2001;74: 288–94. Available: http://www.ncbi.nlm.nih.gov/pubmed/1141085311410853
14. Lin C-W, Tsai M-H, Li S-T, Tsai T-I, Chu K-C, Liu Y-C, et al. A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc Natl Acad Sci U S A. 2015;112: 10611–6. doi: 10.1073/pnas.151345611226253764
15. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123: 2183–92. doi: 10.1172/JCI6570823563315
16. Moore JS, Wu X, Kulhavy R, Tomana M, Novak J, Moldoveanu Z, et al. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. AIDS. 2005;19: 381–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/1575039115750391
17. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 316: 452–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/39271743927174
18. Banda NK, Wood AK, Takahashi K, Levitt B, Rudd PM, Royle L, et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum. 2008;58: 3081–9. doi: 10.1002/art.2386518821684
19. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch J V, Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320: 373–6. doi: 10.1126/science.115431518420934
20. Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol. 2014;192: 5031–8. doi: 10.4049/jimmunol.130161124760152
21. Crispin M, Yu X, Bowden TA, Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci U S A. 2013;110: E3544–6. doi: 10.1073/pnas.131065711023929778
22. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch J V, General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A. 2013;110: 9868–72. doi: 10.1073/pnas.130786411023697368
23. Jefferis R, Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. Nature Publishing Group; 2009;8: 226–234. Available: doi: http://dx.doi.org/10.1038/nrd280419247305
24. Selman MHJ, de Jong SE, Soonawala D, Kroon FP, Adegnika a. a., Deelder a. M, et al. Changes in Antigen-specific IgG1 Fc N-glycosylation Upon Influenza and Tetanus Vaccination. Mol Cell Proteomics. 2012;11: M111.014563–M111.014563. doi: 10.1074/mcp.M111.01456322184099
25. Pucić M, Knezević A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High Throughput Isolation and Glycosylation Analysis of IgG-Variability and Heritability of the IgG Glycome in Three Isolated Human Populations. Mol Cell Proteomics. 2011;10: M111.010090–M111.010090. doi: 10.1074/mcp.M111.01009021653738
26. Jefferis R, Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 2005;21: 11–16. doi: 10.1021/bp040016j15903235
27. Parekh RB, Dwek RA, Rademacher TW, Rheumatoid arthritis as a glycosylation disorder. Br J Rheumatol. 1988;27Suppl 2: 162–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/31358703135870
28. Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A. 2011;108: 20690–4. doi: 10.1073/pnas.110836010822143789
29. Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Aikawa T, Kosuge E, et al. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol. 1989;16: 285–90. Available: http://www.ncbi.nlm.nih.gov/pubmed/24985122498512
30. Adebajo AO, Hazelman BL, IgG glycosylation in association with tropical infections and rheumatoid arthritis in the tropics. Clin Exp Rheumatol. 13: 737–40. Available: http://www.ncbi.nlm.nih.gov/pubmed/88352478835247
31. Knezevic A, Gornik O, Polasek O, Pucic M, Redzic I, Novokmet M, et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology. 2010;20: 959–969. doi: 10.1093/glycob/cwq05120356825
32. Selman MHJ, de Jong SE, Soonawala D, Kroon FP, Adegnika AA, Deelder AM, et al. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics. 2012;11: M111.014563. doi: 10.1074/mcp.M111.014563
33. Anthony RM, Ravetch J V, A novel role for the IgG Fc glycan: The anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010;30: 9–14. doi: 10.1007/s10875-010-9405-6
34. Humphreys IR, Edwards L, Snelgrove RJ, Rae AJ, Coyle AJ, Hussell T, A critical role for ICOS co-stimulation in immune containment of pulmonary influenza virus infection. Eur J Immunol. 2006;36: 2928–38. doi: 10.1002/eji.20063615517039567
35. Alter G, Moody MA, The humoral response to HIV-1: new insights, renewed focus. J Infect Dis. 2010;202Suppl: S315–22. doi: 10.1086/655654
36. Estes JD, Role of collagen deposition in lymphatic tissues and immune reconstruction during HIV-1 and SIV infections. Curr HIV/AIDS Rep. 2009;6: 29–35. Available: http://www.ncbi.nlm.nih.gov/pubmed/1914999419149994
37. Brenchley JM, Douek DC, HIV infection and the gastrointestinal immune system. Mucosal Immunol. Society for Mucosal Immunology; 2008;1: 23–30. doi: 10.1038/mi.2007.119079157
38. Lauc G, Huffman JE, Pučić M, Zgaga L, Adamczyk B, Mužinić A, et al. Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers. PLoS Genet. 2013;9: e1003225. doi: 10.1371/journal.pgen.100322523382691
39. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197: 563–71. doi: 10.1086/52678618275276
40. Mahan AE, Tedesco J, Dionne K, Baruah K, Cheng HD, De Jager PL, et al. A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. J Immunol Methods. 2014; doi: 10.1016/j.jim.2014.12.004
41. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, et al. Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. Cell. Elsevier; 2015;163: 988–98. doi: 10.1016/j.cell.2015.10.027
42. Ackerman ME, Moldt B, Wyatt RT, Dugast A- S, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366: 8–19. doi: 10.1016/j.jim.2010.12.01621192942
43. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999;180: 1338–41. doi: 10.1086/31498810479168